| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $6,373,310 ) |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI112579 | Regulation of T cell exhaustion via 3D chromatin architecture | 000 | 10 | NIH | 1/28/2025 | $624,855 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA270252 | Identifying and characterizing functional noncoding mutations in multiple myeloma | 000 | 3 | NIH | 3/19/2025 | $635,423 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R21AI187674 | C25-modified rifabutin analogs as a novel medicinal chemistry strategy to overcome drug-resistant tuberculosis | 000 | 1 | NIH | 11/13/2024 | $265,650 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R37CA250661 | Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cells | 000 | 4 | NIH | 1/7/2025 | $485,503 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01NS133233 | Neutrophil extracellular traps and associated pathogenesis in TBI: a novel peptide therapeutic strategy. | 000 | 2 | NIH | 2/20/2025 | $398,475 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI184502 | Shorter and more effective oral regimens for M. abscessus pulmonary disease | 000 | 1 | NIH | 1/21/2025 | $895,538 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R21AI190958 | Effects of antifungal drug treatment and immune dysfunction on the evolutionary dynamics of gut-colonizing Candida glabrata | 000 | 1 | NIH | 1/27/2025 | $265,650 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI182977 | Tissue specific immunity to fungal infections | 000 | 1 | NIH | 11/22/2024 | $857,215 |
| | 2025 | 2025 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | 2B2CMS331786 | Integrated Care for Kids (InCK) | 00 | 6 | CMS | 12/16/2024 | $2,000,000 |
| | 2025 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | H79TI083671 | HMH Youth and Family TREE Program | 000 | 2 | SAMHSA | 3/26/2025 | $0 |
| | 2025 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | UG3OD035546 | Enriching ECHO Cohorts with High-risk Pregnancies and Children with Disabilities (Enriching ECHO) | 000 | 2 | NIH | 12/23/2024 | $0 |
| | 2025 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | 2B2CMS331786 | Integrated Care for Kids (InCK) | 06 | 5 | CMS | 10/29/2024 | $0 |
| | 2025 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | 2B2CMS331786 | Integrated Care for Kids (InCK) | 05 | 5 | CMS | 10/4/2024 | $0 |
| | 2025 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI141183 | Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens | 000 | 5 | NIH | 2/28/2025 | $0 |
| | 2025 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA283566 | Nuclear envelope and predisposition to hepatic neoplasia | 001 | 2 | NIH | 2/24/2025 | $8,532 |
| | 2025 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01DE028961 | Dissecting cell composition and drug sensitivity in human adenoid cystic carcinomas (ACCs) | 001 | 6 | NIH | 2/19/2025 | $0 |
| | 2025 | 2023 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | T2249945 | Dental Reimbursement Program | 01 | 1 | HRSA | 12/4/2024 | $0 |
| | 2025 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | U19AI171401 | Metropolitan AntiViral Drug Accelerator | 000 | 1 | NIH | 3/25/2025 | $0 |
| | 2025 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | T1433114 | ANE - Nurse Practitioner Residency Program | 04 | 4 | HRSA | 11/13/2024 | -$63,531 |
| | 2025 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI139874 | Ezh2 regulates follicular helper T cell differentiation | 000 | 6 | NIH | 2/10/2025 | $0 |
| | 2025 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI141805 | A dual-beta-lactam strategy for treating multidrug resistant M abscessus | 000 | 4 | NIH | 2/11/2025 | $0 |
| | 2025 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI132374 | Combatting natural resistance and persistence in non-TB mycobacterial disease | 000 | 6 | NIH | 1/19/2025 | $0 |
| | 2025 | 2022 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI138986 | Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negativebacterial infections | 000 | 5 | NIH | 11/22/2024 | $0 |
| | 2025 | 2021 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA212639 | Targeting Transcriptional Co-repressor CoREST Complex in Melanoma | 000 | 5 | NIH | 11/25/2024 | $0 |
| | 2025 | 2021 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01HD090180 | Epigenetics of Down Syndrome | 000 | 6 | NIH | 11/19/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $21,654,919 ) (Continued on the next page) |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA270252 | Identifying and characterizing functional noncoding mutations in multiple myeloma | 001 | 2 | NIH | 4/22/2024 | $36,996 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI173261 | Celiac and inflammatory bowel diseases: functional post-GWAS approach | 000 | 1 | NIH | 8/20/2024 | $580,274 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI173261 | Celiac and inflammatory bowel diseases: functional post-GWAS approach | 000 | 1 | NIH | 8/20/2024 | $253,250 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | UG3OD035546 | Enriching ECHO Cohorts with High-risk Pregnancies and Children with Disabilities (Enriching ECHO) | 000 | 2 | NIH | 6/10/2024 | $3,669,385 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R21AI168729 | Elucidating mediators of genetic instability in Candida glabrata | 000 | 2 | NIH | 10/25/2023 | $209,973 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R21AI168729 | Elucidating mediators of genetic instability in Candida glabrata | 001 | 2 | NIH | 5/13/2024 | $23,330 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI150765 | Immunometabolic regulations of pulmonary TB pathogenesis by adiposetissue | 001 | 6 | NIH | 5/20/2024 | $76,420 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI150765 | Immunometabolic regulations of pulmonary TB pathogenesis by adiposetissue | 000 | 6 | NIH | 12/22/2023 | $687,767 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA290808 | ID3 regulation of tissue-infiltrating T cells mediating graft-versus-host disease and leukemia rejection | 000 | 1 | NIH | 4/30/2024 | $752,830 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | H79TI083671 | HMH Youth and Family TREE Program | 003 | 2 | SAMHSA | 7/31/2024 | $0 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | H79TI083671 | HMH Youth and Family TREE Program | 002 | 2 | SAMHSA | 5/10/2024 | $543,815 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI177342 | Optimization of rifamycins to overcome intrinsic resistance of nontuberculous mycobacteria to improve treatment of NTM lung disease | 000 | 2 | NIH | 5/20/2024 | $838,280 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | K22CA288932 | Cancer Misinformation and Use of Complementary and Alternative Therapy (CAM) among Patients with Cancer. | 000 | 1 | NIH | 6/28/2024 | $194,400 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R21AA030625 | Peptide therapy for alcohol-induced CNS injury | 000 | 2 | NIH | 5/21/2024 | $210,306 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | K00CA264409 | Optimizing adherence to lung cancer screening: Applying theory and implementation science to participant engagement | 000 | 4 | NIH | 8/21/2024 | $103,871 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01CA263662 | Leveraging Social Media to Increase Lung Cancer Screening Awareness, Knowledge and Uptake in High-Risk Populations | 000 | 4 | NIH | 8/12/2024 | $651,814 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R00CA245123 | Elucidating the Role of SMAD4 in Colorectal Cancer | 000 | 5 | NIH | 6/7/2024 | $249,000 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | H79SM084539 | Hackensack Meridian Carrier Clinic Mental Health Awareness in Identifying Disturbances in Emotions Program (AIDE) | 000 | 4 | SAMHSA | 5/30/2024 | $124,990 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R00CA245488 | Leveraging behavioral science to improve patient understanding of advanced cancer | 001 | 5 | NIH | 4/18/2024 | $24,899 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R00CA245488 | Leveraging behavioral science to improve patient understanding of advanced cancer | 000 | 5 | NIH | 3/21/2024 | $224,101 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI145436 | Translational approaches to improve understanding and outcome in Tuberculous meningitis | 000 | 5 | NIH | 3/20/2024 | $747,157 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI161013 | Harnessing B cells for TB vaccine development to improve therapy of TB and TB-HIV coinfection | 000 | 4 | NIH | 6/7/2024 | $1,273,323 |
| | 2024 | 2024 | HMH HOSPITALS CORPORATION | 343 THORNALL ST | EDISON | NJ | 08837-2206 | MIDDLESEX | USA | R01AI145436 | Translational approaches to improve understanding and outcome in Tuberculous meningitis | 001 | 5 | NIH | 7/17/2024 | $0 |
|
